EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists

Cheng Peng iD, Elizabeth A Vecchio, Anh T N Nguyen, Mia De Seram, Ruby Tang, Peter Keov, Owen L Woodman iD, Yung-Chih Chen, Jonathan Baell, Lauren T May iD, Peishen Zhao iD, Rebecca H Ritchie iD and 1 more

British Journal of Pharmacology · 2024-11 · 181 (22) · 4677-4692

DOI: 10.1111/bph.17310 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2024-08-18. Written by Cheng Peng and 12 co-authors. Institution: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. Major MEDLINE topics: Receptors, Formyl Peptide, Receptors, Lipoxin, Signal Transduction, Protein Transport. Cited 12 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Victorian Government of Australia's Operational Infrastructure Support Program, Monash Graduate Excellence Scholarship, Australian Government Research Training Program Scholarship.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background There is increasing interest in developing FPR2 agonists (compound 43, ACT‐389949 and BMS‐986235) as potential pro‐resolving therapeutics, with ACT‐389949 and BMS‐986235 having entered phase I clinical development. FPR2 activation leads to diverse downstream outputs. ACT‐389949 was observed to cause rapid tachyphylaxis, while BMS‐986235 and compound 43 induced cardioprotective effects in preclinical models. We aim to characterise the differences in ligand‐receptor engagement and downstream signalling and trafficking bias profile. Experimental Approach Concentration‐response curves to G protein dissociation, β ‐arrestin recruitment, receptor trafficking and second messenger signalling were generated using FPR2 ligands (BMS‐986235, ACT‐389949, compound 43 and WKYMVm), in HEK293A cells. Log( τ /K A ) was obtained from the operational model for bias analysis using WKYMVm as a reference ligand. Docking of FPR2 ligands into the active FPR2 cryoEM structure (PDBID: 7T6S) was performed using ICM pro software. Key Results Bias analysis revealed that WKYMVm and ACT‐389949 shared a very similar bias profile. In comparison, BMS‐986235 and compound 43 displayed approximately 5‐ to 50‐fold bias away from β ‐arrestin recruitment and trafficking pathways, while being 35‐ to 60‐fold biased towards cAMP inhibition and pERK1/2. Molecular docking predicted key amino acid interactions at the FPR2 shared between WKYMVm and ACT‐389949, but not with BMS‐986235 and compound 43. Conclusion and Implications In vitro characterisation demonstrated that WKYMVm and ACT‐389949 differ from BMS‐986235 and compound 43 in their signalling and protein coupling profile. This observation may be explained by differences in the ligand‐receptor interactions. In vitro characterisation provided significant insights into identifying the desired bias profile for FPR2‐based pharmacotherapy.

Subjects

MeSH terms (MEDLINE)

Receptors, Formyl PeptideReceptors, LipoxinSignal TransductionProtein TransportHumansHEK293 CellsMolecular Docking Simulationbeta-ArrestinsLigandsDose-Response Relationship, Drug

Author keywords

Aspirin triggered lipoxin A4FPR2internalisationreceptor traffickingresolution of inflammationβ‐arrestin‐2

Substances

Receptors, Formyl PeptideReceptors, LipoxinFPR2 protein, humanbeta-ArrestinsLigands

Authors and institutions

  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Monash Victorian Heart Institute, Blackburn Road Clayton, Monash University, Melbourne, Victoria, Australia.
  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Vitoria, Australia.

ORCID profiles: Cheng Peng, Owen L Woodman, Lauren T May, Peishen Zhao, Rebecca H Ritchie, Cheng Xue Qin

Funding

  • Victorian Government of Australia's Operational Infrastructure Support Program
  • Monash Graduate Excellence Scholarship
  • Australian Government Research Training Program Scholarship
  • National Health and Medical Research Council Early Career Researcher Fellowship
  • National Heart Foundation of Australia
  • Coronary Artery Disease Frontiers Catalyst Grant
  • NHF Future Leader Fellowship
  • Australian Research Council Future Fellowship

Cite

APA

Peng, C., Vecchio, E. A., Nguyen, A. T. N., De Seram, M., Tang, R., Keov, P., Woodman, O. L., Chen, Y. C., Baell, J., May, L. T., Zhao, P., Ritchie, R. H., & Qin, C. X. (2024). Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists. British Journal of Pharmacology, 181(22), 4677-4692. https://doi.org/10.1111/bph.17310

Vancouver

Peng C, Vecchio EA, Nguyen ATN, De Seram M, Tang R, Keov P, et al. Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists. British Journal of Pharmacology. 2024;181(22):4677-4692. doi:10.1111/bph.17310

BibTeX
@article{Peng2024,
  author = {Peng, Cheng and Vecchio, Elizabeth A and Nguyen, Anh T N and De Seram, Mia and Tang, Ruby and Keov, Peter and Woodman, Owen L and Chen, Yung-Chih and Baell, Jonathan and May, Lauren T and Zhao, Peishen and Ritchie, Rebecca H and Qin, Cheng Xue},
  title = {Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {22},
  pages = {4677--4692},
  doi = {10.1111/bph.17310}
}
Start for free →